Spiral Microfluidic Device for Cardiac Cell Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic techniques for cardiovascular diseases (CVDs) are inadequate for early detection and long-term monitoring due to asymptomatic development, low detectable biomarker levels, and the need for sophisticated equipment, leading to potential delays in treatment and increased severity.
Innovation Solution
A spiral microfluidic device that separates and focuses cardiac cells from a blood sample using inertial migration forces, allowing for rapid and sensitive detection of CVD-associated biomarkers, enabling early-stage diagnosis and long-term monitoring with minimal equipment and cost.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional diagnostic techniques are used for CVD detection, then equipment sophistication and complexity are high, but detection speed and sensitivity are insufficient leading to treatment delays
Solution Approach 1:
The blood sample analysis is segmented into distinct functional zones within the microfluidic device: a separation channel that divides cardiac cells from other blood components, and a detection chamber that concentrates biomarkers. This segmentation enables rapid detection by processing different aspects of the sample simultaneously in specialized zones rather than using complex sequential analysis equipment
Solution Approach 2:
The invention employs microfluidic hydraulic principles to drive blood sample flow through the device using pressure gradients, and uses acoustic waves (pneumatic principle) to manipulate and separate cardiac cells from other blood components. This replaces complex mechanical separation equipment with fluid dynamics-based separation, achieving fast processing with minimal equipment
2Measurement precision
If conventional biomarker detection methods are used, then detectable biomarker levels are low especially at early stages, but current methods lack sensitivity leading to false-negative results
Solution Approach 1:
The microfluidic device performs preliminary concentration and purification of cardiac biomarkers from the blood sample before detection. The separation channel pre-enriches cardiac cells and the detection chamber further concentrates biomarkers, so when detection occurs, biomarker levels are already amplified to detectable ranges, eliminating false-negatives at early disease stages
Solution Approach 2:
The invention introduces microfluidic channels and acoustic fields as intermediary mechanisms between the blood sample and detection system. These intermediaries actively manipulate the sample to concentrate rare cardiac biomarkers and isolate cardiac cells, bridging the sensitivity gap between low-abundance biomarkers and detection thresholds
3Productivity
If comprehensive blood analysis is performed to ensure accurate CVD diagnosis, then processing time is extended, but early intervention requires rapid results within treatment windows
Solution Approach 1:
The microfluidic device enables continuous flow analysis where blood sample processing, separation, and detection occur in uninterrupted sequential stages. The sample continuously moves through the separation channel and into the detection chamber without stopping, eliminating idle time between processing steps and enabling rapid comprehensive analysis within the treatment window
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device achieves fast, sensitive, and cost-effective detection of CVDs within two hours, facilitating early intervention and practical point-of-care applications, improving patient outcomes by enabling timely treatment and regular monitoring.
Implementation Method 1
separates and focuses cardiac cells from a blood sample using inertial migration forces
Data Source
AI summary
The present invention relates to a method of diagnosing cardiovascular disease (CVD). The method comprises obtaining a whole blood sample from a subject; separating components of the whole blood sample into a plurality of fluid fractions; collecting one or more selected fluid fractions comprising one or more separated components of the whole blood sample, wherein the one or more separated components comprise cardiac cells such as cardiomyocytes; and detecting expression of one or more cardiovascular disease-associated biomarkers from the cardiomyocytes from the selected fluid fractions thereby determining one or more related cardiovascular diseases in the subject.